- Home
- IMCC vs CERO Comparison
IMCC vs CERO Comparison
Compare IMCC & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- CERO
- Stock Information
- Founded
- IMCC 1980
- CERO 2017
- Country
- IMCC Israel
- CERO United States
- Employees
- IMCC N/A
- CERO N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- CERO
- Sector
- IMCC Health Care
- CERO
- Exchange
- IMCC Nasdaq
- CERO Nasdaq
- Market Cap
- IMCC 12.0M
- CERO 3.5M
- IPO Year
- IMCC N/A
- CERO N/A
- Fundamental
- Price
- IMCC $2.95
- CERO $8.90
- Analyst Decision
- IMCC
- CERO Strong Buy
- Analyst Count
- IMCC 0
- CERO 2
- Target Price
- IMCC N/A
- CERO $45.00
- AVG Volume (30 Days)
- IMCC 148.9K
- CERO 3.3M
- Earning Date
- IMCC 08-13-2025
- CERO 08-13-2025
- Dividend Yield
- IMCC N/A
- CERO N/A
- EPS Growth
- IMCC N/A
- CERO N/A
- EPS
- IMCC N/A
- CERO N/A
- Revenue
- IMCC $37,894,737.00
- CERO N/A
- Revenue This Year
- IMCC $47.12
- CERO N/A
- Revenue Next Year
- IMCC $12.83
- CERO N/A
- P/E Ratio
- IMCC N/A
- CERO N/A
- Revenue Growth
- IMCC 12.68
- CERO N/A
- 52 Week Low
- IMCC $1.29
- CERO $6.71
- 52 Week High
- IMCC $7.12
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- IMCC 51.60
- CERO 46.23
- Support Level
- IMCC $2.37
- CERO $8.50
- Resistance Level
- IMCC $3.75
- CERO $9.73
- Average True Range (ATR)
- IMCC 0.38
- CERO 1.20
- MACD
- IMCC 0.03
- CERO -0.01
- Stochastic Oscillator
- IMCC 41.99
- CERO 14.54
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.